Literature DB >> 19321396

Intrahepatic cholangiocarcinoma associated with intrahepatic duct stones.

Hoon Hur1, Il-Young Park, Gi-Young Sung, Do-Sang Lee, Wook Kim, Jong-Man Won.   

Abstract

OBJECTIVE: It has been well established that the long-term prognosis of intrahepatic duct stones (IHDS) is complicated by the late development of biliary cirrhosis with associated intrahepatic cholangiocarcinoma (IHCC). Despite recent improvements in imaging studies, accurate preoperative diagnosis of IHCC is difficult. Therefore, we attempted to elucidate the clinical features of patients with IHDS with IHCC.
METHODS: We reviewed 80 patients with IHDS and divided them into two groups. The DS group included 72 patients who had only IHDS. The second group was defined as the CC group and included eight patients who had IHDS and IHCC. For diagnosis of IHDS and confirmation of coexisting IHCC, patients underwent various radiological evaluations and additional laboratory tests, such as serum carbohydrate antigen 19-9 (CA 19-9).
RESULTS: There was no significant difference in the symptoms and stone characteristics between the two groups. For the CC group, liver resection was performed in four patients. Three patients underwent curative resection, but only one of these patients was alive at 36 months without recurrence.
CONCLUSION: IHCC with IHDS was difficult to diagnose in the early phase. Therefore, while performing diagnostic studies and surgery for IHDS, one should always consider the possibility of coexisting cholangiocarcinoma.

Entities:  

Mesh:

Year:  2009        PMID: 19321396     DOI: 10.1016/S1015-9584(09)60002-6

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  7 in total

1.  Establishment and identification of the human multi-drug-resistant cholangiocarcinoma cell line QBC939/ADM.

Authors:  Zhi-Hua Liu; Yan-Ping He; Yukun Zhou; Peng Zhang; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2010-01-29       Impact factor: 2.316

2.  Cholangiocarcinoma Risk as Long-term Outcome After Hepatic Resection in the Hepatolithiasis Patients.

Authors:  Hyo Jung Kim; Jae Seon Kim; Sang Jun Suh; Beom Jae Lee; Jong-Jae Park; Hong Sik Lee; Chang Duck Kim; Young-Tae Bak
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

Review 3.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

4.  Comparison of concomitant and subsequent cholangiocarcinomas associated with hepatolithiasis: Clinical implications.

Authors:  Chia-Cheng Lin; Ping-Yi Lin; Yao-Li Chen
Journal:  World J Gastroenterol       Date:  2013-01-21       Impact factor: 5.742

5.  The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939.

Authors:  Zhi-Hua Liu; Yan-Ping He; Huanlong Qin
Journal:  Mol Biol Rep       Date:  2009-09-13       Impact factor: 2.316

6.  Predicting peritumoral Glisson's sheath invasion of intrahepatic cholangiocarcinoma with preoperative CT imaging.

Authors:  Yingfan Mao; Yong Zhu; Yudong Qiu; Weiwei Kong; Liang Mao; Qun Zhou; Jun Chen; Jian He
Journal:  Quant Imaging Med Surg       Date:  2019-02

7.  Effect of the GLP-1 analog exendin-4 and oxaliplatin on intrahepatic cholangiocarcinoma cell line and mouse model.

Authors:  Ben-Dong Chen; Wen-Chao Zhao; Qing-An Jia; Wen-Yan Zhou; Yang Bu; Zuo-Zheng Wang; Feng Wang; Wu-Jun Wu; Qi Wang
Journal:  Int J Mol Sci       Date:  2013-12-13       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.